Current Limits of NAD+ Research

Current NAD+ research is limited by differences between interventions, uncertain tissue-specific translation, incomplete understanding of human NAD+ biology across age and disease states, reliance on surrogate biomarkers, relatively small or short clinical studies, mixed functional outcomes, and major gaps between preclinical findings and demonstrated human effects. These limitations do not make NAD+ research uninformative, but they restrict how confidently biochemical and animal findings can be translated into claims about energy, recovery, healthy ageing, disease modification, or longevity.

These evidence boundaries are central to NAD+ research. NAD+ participates in fundamental metabolic and signaling pathways, but the scientific importance of a pathway does not establish that increasing NAD+ through a particular intervention will produce a defined human outcome.

This article is provided for general educational purposes and explains terminology, evidence, and regulatory concepts associated with NAD+ research. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A biochemical pathway, animal experiment, increase in NAD+, commercial infusion program, precursor study, testimonial, patent, or clinical-trial registration does not by itself establish clinical effectiveness, greater energy, faster recovery, healthier ageing, longer lifespan, an appropriate amount, or suitability for a particular use.

NAD+ Research Is Not One Intervention

One of the largest limitations in discussing NAD+ research is the tendency to combine different interventions into one evidence category.

Human and preclinical research may involve:

• NAD+ itself
• nicotinamide riboside
• nicotinamide mononucleotide
• nicotinamide
• nicotinic acid
• other NAD-related compounds

These substances participate in related metabolic pathways but should not be treated automatically as interchangeable interventions.

NAD+ Precursors Are Not Equivalent to Direct NAD+ Administration

A precursor must enter metabolic pathways before contributing to NAD+ synthesis or recycling.

Direct NAD+ administration presents different questions involving:

• extracellular metabolism
• cellular uptake
• conversion to related metabolites
• route-specific exposure
• distribution
• clearance

Evidence from oral NR or NMN therefore cannot automatically establish the effects of intravenous NAD+.

NR and NMN Should Also Be Evaluated Separately

Nicotinamide riboside and nicotinamide mononucleotide are chemically distinct compounds.

They may differ in:

• absorption
• transport
• metabolic conversion
• tissue exposure
• formulation
• human study history

A finding involving one precursor should not be attributed automatically to the other.

Commercial NAD+ Products May Differ From Research Formulations

A clinical study evaluates a particular formulation under defined manufacturing and administration conditions.

A commercially offered product may differ in:

• concentration
• purity
• buffer
• pH
• route
• infusion rate
• storage
• combination ingredients

A shared NAD+ label does not establish equivalence between a commercial product and a research formulation.

Route-Specific Evidence Remains Limited

Oral, intravenous, intramuscular, and other NAD-related administration routes should be evaluated separately.

Route can influence:

• absorption
• peak concentrations
• systemic exposure
• metabolite formation
• first-pass metabolism
• administration-related safety

A result from one route should not automatically be presented as evidence for another.

Human Evidence for Intravenous NAD+ Is More Limited Than Precursor Research

Much of the recent human NAD+ literature involves oral precursors such as NR and NMN rather than direct intravenous NAD+ administration.

This creates an important evidence gap when commercial intravenous NAD+ services make claims involving:

• energy
• recovery
• mental clarity
• healthy ageing
• metabolic improvement

Those claims require evidence involving the actual intravenous intervention and the claimed outcome.

Infusion Protocols May Not Be Standardized

Commercial NAD+ infusion protocols may differ in:

• total amount
• infusion concentration
• infusion duration
• frequency
• combination ingredients
• monitoring procedures

Differences in protocol make it difficult to transfer findings between settings without a defined comparison.

NAD+ Measurement Itself Has Limitations

NAD+ and related metabolites require careful sample handling and analytical measurement.

Results can be influenced by:

• sample type
• time to processing
• temperature
• storage
• extraction
• analytical platform
• reference standards

Differences in methodology can contribute to differences between studies.

Different Biological Compartments Give Different Information

Researchers may measure NAD-related metabolites in:

• whole blood
• plasma
• serum
• blood cells
• skeletal muscle
• urine
• other tissues

A measurement from one compartment does not establish concentrations throughout the body.

Blood NAD+ Does Not Represent Every Tissue

Blood measurements are relatively accessible but cannot establish NAD+ concentrations in:

• brain
• liver
• heart
• skeletal muscle
• adipose tissue

Tissue-specific claims require evidence from the relevant tissue or a sufficiently validated surrogate.

Human Tissue Data Remain Sparse

Compared with the extensive animal and cellular literature, direct human tissue NAD+ measurements remain relatively limited.

This restricts conclusions about:

• which human tissues decline with age
• which tissues respond to supplementation
• how large the response is
• how long the response lasts
• whether the response relates to function

The Age-Related NAD+ Decline Narrative Is More Complex in Humans

Age-related declines in NAD+ are well described in many experimental models.

Human findings are less uniform.

Differences can depend on:

• tissue
• assay
• sample type
• participant health
• age range

A general statement that all human NAD+ levels decline steadily with age can therefore overstate the available evidence.

Whole-Blood NAD+ May Not Be a Universal Ageing Marker

Recent human research has challenged the assumption that whole-blood NAD+ follows one simple age-related decline.

This limits attempts to use one blood value as proof of:

• accelerated ageing
• NAD+ deficiency
• biological-age reversal
• successful anti-ageing intervention

Biological Age Is Not the Same as NAD+ Concentration

Biological ageing involves multiple systems and processes.

These can include:

• epigenetic changes
• metabolic changes
• immune changes
• muscle loss
• vascular changes
• cognitive changes
• frailty

No single NAD+ measurement captures the complete ageing process.

Biomarker Changes Are Easier to Demonstrate Than Clinical Effects

Human studies of NAD+ precursors frequently show that NAD-related biomarkers can be increased.

This establishes biochemical target engagement under the study conditions.

Functional outcomes are less consistent.

Target Engagement Is Not Clinical Effectiveness

A rise in NAD+ or a related metabolite can show that an intervention altered NAD-related metabolism.

It does not establish:

• improved physical function
• less fatigue
• better cognition
• faster exercise recovery
• slower ageing
• longer lifespan

These are separate outcome questions.

Biomarkers May Not Be Validated Surrogates

A biomarker can be useful for understanding pathway engagement without being a validated substitute for a clinical endpoint.

Validation would require evidence that changes in the biomarker reliably predict changes in outcomes that matter to people.

Many NAD-related measurements do not currently have that level of validation for broad claims about healthy ageing or energy.

Higher NAD+ Is Not Automatically Better

Many biological systems function within ranges rather than according to a simple more-is-better relationship.

Increasing NAD+ does not automatically establish:

• greater metabolic efficiency
• better mitochondrial function
• more physical energy
• better health

The relevant concentration-response relationships in humans remain incompletely defined.

The Magnitude of a Biomarker Change May Have Uncertain Meaning

A study may report a substantial percentage increase in NAD+.

The clinical significance depends on:

• baseline level
• tissue measured
• duration
• natural variability
• functional outcomes
• safety

A large biochemical effect can coexist with a small or absent functional effect.

Biomarker Changes Can Be Temporary

NAD-related measurements may increase during treatment and later return toward baseline.

A transient biochemical effect does not establish a durable clinical effect.

Functional Outcomes in Human Trials Are Mixed

Human NAD+ precursor trials have reported a combination of:

• positive biomarker findings
• null functional outcomes
• positive secondary outcomes
• population-specific findings
• exploratory effects

This mixed pattern should be preserved rather than summarized as universal benefit.

Null Results Are Scientifically Important

A trial that increases NAD+ but does not improve a predefined functional endpoint provides important information.

It may indicate that:

• raising the biomarker is insufficient
• the population does not benefit on that endpoint
• the intervention duration was inadequate
• the pathway is not limiting function

Primary Outcomes Should Not Be Replaced by Positive Secondary Findings

If a study's primary endpoint is not met, a positive exploratory biomarker or subgroup result should not be used to imply that the trial established the primary clinical claim.

Multiple Comparisons Can Produce Chance Findings

Trials may measure numerous metabolites, proteins, physiological measures, and functional outcomes.

The more comparisons performed, the greater the possibility that some differences appear statistically significant by chance.

Readers should distinguish:

• predefined primary endpoints
• secondary endpoints
• exploratory endpoints
• post hoc analyses

Small Trials Remain a Major Limitation

Many NAD-related human studies include relatively few participants.

Small studies can limit:

• statistical precision
• detection of modest effects
• subgroup analysis
• generalizability
• rare adverse-event detection

Small Positive Studies Need Replication

A result in a small trial may be real while still producing an imprecise estimate of effect size.

Replication in larger independent populations helps determine whether the effect is:

• reproducible
• clinically meaningful
• population specific
• method dependent

Short Trial Duration Limits Healthy-Aging Conclusions

Many studies last weeks or months.

Healthy ageing develops over years and decades.

A short trial cannot establish effects on:

• lifespan
• long-term frailty
• age-related disability
• major disease incidence
• long-term cognition

Lifespan Cannot Be Inferred From Biomarkers

Animal studies can measure lifespan directly.

Most human NAD-related studies cannot.

An increase in NAD+ should therefore not be interpreted as evidence that human lifespan has been extended.

Healthspan Is Difficult to Measure

Healthspan is a broad concept involving years lived with functional health.

Possible human healthspan measurements might involve:

• mobility
• frailty
• cognition
• independence
• chronic disease
• quality of life

NAD+ concentration alone cannot establish healthspan.

Animal Longevity Results Have Major Translation Limits

Rodent studies have contributed substantially to NAD+ ageing hypotheses.

Human translation is limited by differences in:

• lifespan
• metabolic rate
• diet
• environment
• disease patterns
• experimental control

A longevity finding in a rodent model should remain described as a preclinical finding.

Animal Doses May Be Difficult to Translate

Animal studies may use amounts selected to produce clear experimental pathway effects.

Human translation requires consideration of:

• pharmacokinetics
• body size
• metabolism
• route
• formulation
• safety

Simple dose conversion cannot establish an appropriate human intervention.

Genetically Modified Animal Models Have Additional Limits

Some NAD+ research uses animals with altered genes involved in NAD metabolism, ageing, or disease.

These models can help identify pathways but may not reproduce ordinary human biology.

Cell Studies Bypass Whole-Body Pharmacology

Cell experiments may expose cells directly to NAD-related compounds.

They can bypass:

• absorption
• distribution
• metabolism
• clearance
• organ interactions
• immune responses

A cellular effect should not automatically be expected after human administration.

High Experimental Concentrations Can Be Difficult to Reproduce in Humans

Laboratory studies may use concentrations selected to clarify mechanisms.

Researchers need to determine whether comparable exposure is:

• achievable
• sustained
• safe
• present in the relevant human tissue

Mitochondrial Claims Often Extend Beyond the Data

NAD+ is central to mitochondrial metabolism, which can lead to simplified claims that increasing NAD+ improves mitochondrial function.

Mitochondrial performance can involve:

• respiration
• ATP production
• membrane potential
• substrate use
• organelle turnover

A change in one NAD-related marker does not establish improvement across all mitochondrial functions.

Gene-Expression Changes Have Limited Clinical Meaning by Themselves

Some studies identify changes in genes related to metabolism, stress responses, or mitochondria.

Gene expression does not necessarily establish:

• protein-level change
• functional change
• clinical benefit

Sirtuin Mechanisms Are Frequently Overgeneralized

Sirtuins are NAD+-dependent enzymes involved in multiple cellular processes.

Experimental evidence linking NAD+ with sirtuin biology does not automatically establish:

• slower human ageing
• greater longevity
• improved cognition
• better exercise performance

PARP Biology Is Also More Complex Than a Wellness Claim

PARPs use NAD+ in cellular responses including DNA-damage signaling.

A relationship between NAD+ availability and PARP biology does not mean that NAD+ administration has been shown to improve DNA repair clinically in humans.

CD38-Related Mechanisms Are Still Translational Questions

CD38 is one of the enzymes involved in NAD+ consumption.

Experimental changes involving CD38 and NAD+ metabolism can contribute to ageing hypotheses.

They do not independently establish that modifying NAD+ levels produces healthier ageing in humans.

Energy Claims Remain Poorly Defined

The word energy can refer to cellular metabolism or a subjective feeling.

A meaningful human energy claim would require defined outcomes such as:

• fatigue scores
• physical activity
• exercise capacity
• work performance
• validated vitality measures

Recovery Claims Need Direct Human Testing

Recovery after exercise, illness, or physical stress involves multiple systems.

A recovery trial may need to measure:

• strength restoration
• performance recovery
• soreness
• functional status
• time to baseline

An NAD+ biomarker increase does not establish these outcomes.

Healthy-Aging Claims Require Long-Term Human Evidence

Healthy ageing involves more than one metabolic pathway.

Claims involving healthy ageing require appropriately designed human outcomes addressing function over meaningful periods.

The evidence requirement is discussed further in why NAD+ energy, recovery, and healthy-aging claims require human evidence.

Biomarker Claims Should Remain Biomarker Claims

If a study shows an increase in whole-blood NAD+, the accurate conclusion is that the measured whole-blood NAD+ value increased under the study conditions.

It should not automatically become a claim involving:

• greater energy
• better recovery
• slower ageing
• improved organ function

The Difference Between Biomarkers and Outcomes Is Fundamental

This distinction is examined in why NAD+ biomarker changes do not automatically establish clinical outcomes.

Biochemical target engagement can be an important stage of research without being the final clinical endpoint.

Population Differences Limit Generalization

NAD-related studies may enroll:

• healthy young adults
• middle-aged adults
• older adults
• people with obesity
• people with metabolic conditions
• other selected groups

A finding from one population should not automatically be generalized to another.

Baseline NAD+ Status May Influence Response

Participants may differ in baseline NAD-related metabolism.

The significance of these differences and whether they predict response remain active research questions.

Diet Can Affect NAD-Related Metabolism

NAD+ metabolism is connected to nutrients involved in vitamin B3 pathways.

Dietary differences can therefore complicate interpretation if they are not considered in study design.

Physical Activity Can Influence Metabolic Outcomes

Exercise can affect mitochondrial metabolism, insulin sensitivity, cardiovascular function, and other outcomes frequently studied in NAD+ research.

Trials should account for major differences in participant activity whenever relevant.

Medication Use Can Create Additional Variables

Human participants may use medications that affect:

• glucose metabolism
• lipids
• blood pressure
• inflammation
• energy metabolism

These factors can complicate attribution of an observed change to an NAD-related intervention.

The Microbiome Adds Another Layer of Complexity

Gut microbes can participate in metabolism of dietary and supplemented compounds.

Microbiome differences may contribute to variability in responses to some NAD-related precursors.

The importance of this effect in humans remains an active area of research.

Interindividual Variability Can Be Large

Group averages can conceal substantial variation between participants.

Some people may show larger biochemical responses while others show smaller responses.

The reasons may involve:

• baseline metabolism
• genetics
• diet
• microbiome
• age
• health status

Responder Analyses Need Careful Interpretation

Dividing participants into responders and non-responders after observing the data can generate hypotheses.

It does not necessarily establish a validated method for predicting who will benefit.

Safety Data Are Often Short Term

Many human NAD+ precursor studies report short-term tolerability.

This does not establish safety over years of repeated exposure.

Rare Adverse Events Require Large Populations

Small trials may be unable to identify events that occur infrequently.

Larger studies and broader surveillance may be needed to characterize rare risks.

Long-Term Metabolic Effects Remain Incompletely Characterized

Prolonged manipulation of NAD-related pathways could potentially influence multiple biological processes.

Long-term human studies are needed to characterize whether sustained changes have:

• beneficial effects
• neutral effects
• unexpected effects

The direction should not be assumed from short-term pathway biology.

Safety May Differ Between NAD-Related Compounds

NR, NMN, nicotinamide, and direct NAD+ administration can produce different metabolites and exposures.

Safety evidence for one intervention should not automatically be transferred to another.

Intravenous Administration Has Route-Specific Safety Questions

An infusion introduces additional considerations involving:

• infusion rate
• vascular access
• formulation sterility
• endotoxin control
• compatibility
• administration reactions

Oral precursor safety studies do not answer these route-specific questions.

Combination Infusions Are Difficult to Interpret

Commercial infusion programs may combine NAD+ with vitamins, minerals, amino acids, or other substances.

Combination administration makes it more difficult to determine:

• which component caused a biomarker change
• which component influenced symptoms
• which component contributed to an adverse event

Evidence for NAD+ alone does not establish evidence for a multi-ingredient infusion.

Testimonials Do Not Resolve Evidence Gaps

People may report improvements in energy, recovery, concentration, or wellbeing after NAD-related interventions.

These reports generally cannot control for:

• expectation
• placebo effects
• concurrent treatments
• hydration
• sleep
• natural variation

Commercial Availability Does Not Establish Clinical Evidence

A treatment being offered by a clinic or sold online does not establish that it has demonstrated the advertised outcome in controlled human research.

Mechanistic Plausibility Is Not Clinical Confirmation

A claim can be biologically plausible while remaining clinically unproven.

NAD+ research contains many plausible mechanisms.

Human outcome studies are needed to determine which mechanisms translate into meaningful effects.

Publication Bias Can Distort the Visible Evidence

Positive or unusual findings may be more likely to be published and discussed than null findings.

A balanced review should include:

• positive studies
• null studies
• inconclusive studies
• registered studies without published results

Review Articles Can Give the Appearance of a Larger Evidence Base

Multiple reviews may cite the same small collection of primary studies.

The number of reviews should not be confused with the number of independent clinical trials.

Human Evidence Should Be Evaluated Study by Study

A systematic approach should identify:

• the exact compound
• route
• formulation
• population
• sample size
• duration
• primary endpoint
• biomarkers
• functional outcomes
• safety findings

The broader framework is described in how human NAD+ research should be evaluated.

What Current NAD+ Research Can Establish

Depending on the specific study, current evidence can help establish:

• NAD+ pathway biology
• effects of selected interventions on NAD-related biomarkers
• pharmacokinetic patterns
• short-term tolerability
• selected metabolic or functional outcomes

Each conclusion should remain linked to the intervention and conditions that generated it.

What Current Research Cannot Establish Automatically

The existing evidence does not automatically establish:

• equivalence between NAD+ and its precursors
• equivalence between oral and intravenous administration
• greater subjective energy from higher NAD+
• faster recovery
• reversal of human ageing
• extension of human lifespan
• long-term safety of every NAD-related intervention

Where Further Human Research Is Needed

Further research could clarify:

• tissue-specific NAD+ changes
• long-term clinical outcomes
• route-specific pharmacokinetics
• direct intravenous NAD+ effects
• functional effects in defined populations
• long-term safety
• relationships between biomarkers and meaningful outcomes

Final Perspective

Current NAD+ research provides strong biological reasons to study NAD-related metabolism and growing evidence that selected interventions can change NAD-related biomarkers in humans.

The major limitation is that biochemical target engagement is more consistently demonstrated than broad clinical outcomes, while evidence remains uneven across compounds, routes, tissues, populations, and study durations.

Accurate coverage should distinguish NAD+ itself from its precursors, blood measurements from tissue measurements, biomarker changes from clinical outcomes, animal findings from human findings, and short-term studies from long-term healthy-ageing conclusions. Current evidence should therefore be described according to what each study directly establishes rather than extended into unsupported claims about energy, recovery, anti-ageing effects, or longevity.